SinoMab Bioscience Overview

  • Founded
  • 2002

Founded
  • Status
  • Public

  • Employees
  • 283

Employees
  • Stock Symbol
  • 03681

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $0.26

  • (As of Wednesday Closing)

SinoMab Bioscience General Information

Description

SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.

Contact Information

Website
www.sinomab.com
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Delivery
Stock Exchange
HKG
Primary Office
  • Units 303 and 305 to 307, Number 15 Science Park West Avenue
  • Hong Kong Science Park, Pak Shek Kok
  • Hong Kong
+852 3426 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SinoMab Bioscience Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.26 $0.25 $0.24 - $0.46 $256M 1.01B 100K -$0.04

SinoMab Bioscience Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 369,047 369,047 584,092 434,917
Revenue 4,013 4,013 0 0
EBITDA (43,123) (43,123) (18,362) (38,851)
Net Income (44,632) (44,632) (17,746) (39,985)
Total Assets 163,420 163,420 172,887 183,536
Total Debt 43,215 43,215 14,975 7,663
Public Fundamental Data provided by Morningstar, Inc. disclaimer

SinoMab Bioscience Patents

SinoMab Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3867280-A1 Methods of treating rheumatoid arthritis Pending 18-Oct-2018 00000000000
US-20210363246-A1 Method of modulating autoimmunity by disrupting cis-ligand binding of siglec type antigens Pending 18-Oct-2018 00000000000
EP-3867277-A1 Method of modulating autoimmunity by disrupting cis-ligand binding of siglec type antigens Pending 18-Oct-2018 00000000000
US-20210380685-A1 Methods of treating rheumatoid arthritis Pending 18-Oct-2018 00000000000
EP-3708165-A1 Crystal form i of a 5-aminopyrazole carboxamide compound as btk inhibitor Pending 10-Nov-2017 C07D401/14
To view SinoMab Bioscience’s complete patent history, request access »

SinoMab Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SinoMab Bioscience Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 31-Jul-2020 000000000 000 Drug Delivery
To view SinoMab Bioscience’s complete investments history, request access »